NCT06163547 Middle Meningeal Artery Embolization for Chronic Subdural Hematomas (STORMM)
| NCT ID | NCT06163547 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Geneva |
| Condition | Chronic Subdural Hematomas |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2025-02-18 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 180 participants in total. It began in 2025-02-18 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic Subdural Hematomas (cSHD) are common, and due to cerebral compression, often result in neurological impairment and reduced consciousness. Surgery is typically performed once neurological symptoms develop. Recent studies suggest that arteries nourished by the middle meningeal artery (MMA) may be responsible for hematoma progression and that MMA embolization is clinically useful. There is less evidence, that embolization of MMA also may be a treatment option for individuals without surgical treatment. The investigators propose a multicentre study to investigate both potentials: (1) Assessment of efficacy of embolization after surgery to reduce recurrence and improve outcomes by conducting a randomized trial (randomization arms; Arms 1 and 2), (2) Assessment of embolization-alone efficacy when surgery is contraindicated or refused (embolization-only arm, Arms 3 and 4).
Eligibility Criteria
Inclusion Criteria: * Age: 18-100 * Consent possible * cSDH located at the convexities * Patients with symptomatic cSDH * Patients with asymptomatic large chronic/subacute hematoma after 6 weeks of failed conservative treatment Exclusion Criteria: * Consent not possible * Pregnancy * Prisoner * Angiography contraindication * Patient for whom follow-up is problematic (e.g. distant residency, homeless …) * Previous surgery for cSDH
Contact & Investigator
Aria Nouri
PRINCIPAL INVESTIGATOR
University Hospital, Geneva
Frequently Asked Questions
Who can join the NCT06163547 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Chronic Subdural Hematomas. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06163547 currently recruiting?
Yes, NCT06163547 is actively recruiting participants. Contact the research team at aria.nouri@hug.ch for enrollment information.
Where is the NCT06163547 trial being conducted?
This trial is being conducted at Geneva, Switzerland, Lugano, Switzerland.
Who is sponsoring the NCT06163547 clinical trial?
NCT06163547 is sponsored by University Hospital, Geneva. The principal investigator is Aria Nouri at University Hospital, Geneva. The trial plans to enroll 180 participants.